Company Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases.
Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer’s disease and Parkinson’s disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
The company’s drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer’s disease.
Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer.
The company was incorporated in 2004 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Christopher Missling |
Contact Details
Address: 630 5th Avenue, 20th Floor New York, New York 10111 United States | |
| Phone | 844 689 3939 |
| Website | anavex.com |
Stock Details
| Ticker Symbol | AVXL |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001314052 |
| CUSIP Number | 032797300 |
| ISIN Number | US0327973006 |
| Employer ID | 98-0608404 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher U. Missling M.B.A., M.S., Ph.D. | President, Chief Executive Officer, Secretary and Director |
| Sandra Boenisch CPA, CGA | Principal Financial Officer and Treasurer |
| Dr. Walter E. Kaufmann M.D. | Chief Scientific Officer |
| Clint Tomlinson | Vice President of Corporate |
| Dr. Adebayo Laniyonu Ph.D. | Senior Vice President of Nonclinical Development |
| Dr. Edward R Hammond M.D., M.P.H., Ph.D. | Chief Medical Officer |
| Dr. Kun Jin Ph.D. | Head of Biostatistics |
| David Goldberger R.Ph. | Senior Vice President of Regulatory Affairs |
| Dr. Terrie Kellmeyer Ph.D. | Senior Vice President of Clinical Development |
| Dr. Juan Carlos Lopez-Talavera M.D., Ph.D. | Senior Vice President and Head of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Jul 30, 2024 | 8-K | Current Report |
| Jul 29, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 21, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| May 6, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 6, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 28, 2024 | 144 | Filing |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |